At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 615 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Ustekinumab 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Placebo, Ustekinumab 45 mg, and 1 other intervention for Arthritis, Psoriatic. Completed, enrolled 615 participants across 102 sites in 14 countries.
Detailed Summary
The purpose of this study is to evaluate the effectiveness (improvement of signs and symptoms) and safety of ustekinumab in participants with active psoriatic arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Psoriatic
CountriesAustralia, Austria, Canada, Finland, Germany, Hungary, Latvia, Lithuania, New Zealand, Poland, Russia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartDec 2009
Primary CompletionOct 2011
Study CompletionMay 2013
TodayJul 2026
First PostedNov 6, 2009
Enrollment StartDec 1, 2009
Primary CompletionOct 1, 2011
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.7 years ago
Interventions
Placebodrug
SC injections
Ustekinumab 45 mgdrug
SC injections
Ustekinumab 90 mgdrug
SC injections